Changes in average BD, PD, and TP of rhizosphere soil (0–60 cm) under different treatments before and after the experiment. by Hongyi Pan (5706971)

Subjects:

Baseline Characteristics of Study Participants. by Swati M. Surkar (8399427)

“…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”

Raw and processed data files. by Swati M. Surkar (8399427)

“…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”

Linear regression equation and concentration range of each SCFAs standard. by Shudan Liu (7049483)

Subjects:

YFV-Asibi cap0 grows slower and to reduced viral titers in secondary tissues after intrathoracic injection. by Anja vom Hemdt (19787189)

Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs. by Aga E. Gelgie (17661720)

Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

“…In comparison to the parent strain, the 0690::Tn mutant displayed markedly reduced fitness, as evidenced by a significant decrease or even absence in post-challenge mycoplasma counts in murine and cow mammary tissues, respectively. …”

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

“…In comparison to the parent strain, the 0690::Tn mutant displayed markedly reduced fitness, as evidenced by a significant decrease or even absence in post-challenge mycoplasma counts in murine and cow mammary tissues, respectively. …”

Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Open data. by Larissa Brazolotto Ferreira (17671168)

“…</p><p>Results</p><p>There was a significant decrease in BMD in the lumbar spine (1.107 ± 0.109 and 1.075 ± 0.112 g/cm²; <i><i>p</i></i> < 0.001), total body (1.135 ± 0.086 and 1.119 ± 0.085 g/cm²; <i><i>p</i></i> < 0.001), and total proximal femur over the six months of EBF compared to the values obtained from the same EBF group at 15 days postpartum (mean percentage decreases in BMD of −3.4 ± 3.7% (<i><i>p</i></i> < 0.001) in lumbar spine, −2.5 ± 3.4% (<i><i>p</i></i> < 0.001) in total proximal femur, and −1.7 ± 1.9% (<i><i>p</i></i> = 0.001) in total body). …”

Pseudocode of the simulation program (see Supplementary Materials for <i>R</i> codes S1 File). by Farrokh Habibzadeh (12256529)

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Excel data extraction. by Berihun Agegn Mengistie (18781020)

“…The statistical analysis was carried out using STATA version 17, which includes descriptive analysis, forest plots for prevalence, funnel plot, and an Egger test to examine publication bias. A random-effects model was used to determine the pooled effect estimate. …”

Results for fibrin dominant clots: (A) time to recanalize <i>in vitro</i> model; (B) relative clot reduction; (C) RBC release; (D) relative clot degradation rate. by Sandra Thalerová (11434762)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)